NO961113D0 - Behandling og forebyggelse av prostatakreft - Google Patents
Behandling og forebyggelse av prostatakreftInfo
- Publication number
- NO961113D0 NO961113D0 NO961113A NO961113A NO961113D0 NO 961113 D0 NO961113 D0 NO 961113D0 NO 961113 A NO961113 A NO 961113A NO 961113 A NO961113 A NO 961113A NO 961113 D0 NO961113 D0 NO 961113D0
- Authority
- NO
- Norway
- Prior art keywords
- prevention
- treatment
- prostate cancer
- prostate
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/407,822 US5635197A (en) | 1995-03-21 | 1995-03-21 | Treatment and prevention of prostatic cancer metastasis |
| US08/408,745 US5629007A (en) | 1995-03-21 | 1995-03-21 | Method of preventing prostatic cancer development |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO961113D0 true NO961113D0 (no) | 1996-03-19 |
| NO961113L NO961113L (no) | 1996-09-23 |
Family
ID=27020024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO961113A NO961113L (no) | 1995-03-21 | 1996-03-19 | Behandling og forebyggelse av prostatakreft |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0733365A3 (no) |
| JP (1) | JPH08277220A (no) |
| KR (1) | KR960034202A (no) |
| AU (1) | AU695860B2 (no) |
| CA (1) | CA2172211A1 (no) |
| CZ (1) | CZ287977B6 (no) |
| HU (1) | HUP9600702A3 (no) |
| IL (1) | IL117537A (no) |
| MX (1) | MX9601031A (no) |
| NO (1) | NO961113L (no) |
| SG (1) | SG47093A1 (no) |
| TW (1) | TW450809B (no) |
| YU (1) | YU16196A (no) |
| ZA (1) | ZA962141B (no) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5550134A (en) * | 1995-05-10 | 1996-08-27 | Eli Lilly And Company | Methods for inhibiting bone loss |
| IL129689A0 (en) * | 1996-10-30 | 2000-02-29 | Lilly Co Eli | Synthesis of benzo (F) quinolinones |
| US6111110A (en) * | 1996-10-30 | 2000-08-29 | Eli Lilly And Company | Synthesis of benzo[f]quinolinones |
| CA2338298A1 (en) * | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Tricyclic compounds |
| US6436489B1 (en) | 1999-03-24 | 2002-08-20 | Clariant International Ltd. | Fluorine-containing benzothiazoles, and their use in liquid-crystalline mixtures |
| GB0419850D0 (en) * | 2004-09-07 | 2004-10-13 | Angeletti P Ist Richerche Bio | Therapeutic agents |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0591583B1 (en) * | 1991-08-21 | 2001-12-19 | Eli Lilly And Company | Benzo (f) quinolinones as 5-alpha-reductase inhibitors |
| US5239075A (en) * | 1991-08-21 | 1993-08-24 | Eli Lilly And Company | Process for the preparation of benzo (f) quinolinones |
-
1996
- 1996-03-15 TW TW085103095A patent/TW450809B/zh active
- 1996-03-15 SG SG1996006549A patent/SG47093A1/en unknown
- 1996-03-15 ZA ZA9602141A patent/ZA962141B/xx unknown
- 1996-03-18 IL IL11753796A patent/IL117537A/xx not_active IP Right Cessation
- 1996-03-19 CZ CZ1996825A patent/CZ287977B6/cs unknown
- 1996-03-19 AU AU48168/96A patent/AU695860B2/en not_active Ceased
- 1996-03-19 EP EP96301846A patent/EP0733365A3/en not_active Withdrawn
- 1996-03-19 MX MX9601031A patent/MX9601031A/es not_active IP Right Cessation
- 1996-03-19 NO NO961113A patent/NO961113L/no not_active Application Discontinuation
- 1996-03-19 KR KR1019960007405A patent/KR960034202A/ko not_active Application Discontinuation
- 1996-03-19 YU YU16196A patent/YU16196A/sh unknown
- 1996-03-20 CA CA002172211A patent/CA2172211A1/en not_active Abandoned
- 1996-03-20 HU HU9600702A patent/HUP9600702A3/hu unknown
- 1996-03-21 JP JP8064428A patent/JPH08277220A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU695860B2 (en) | 1998-08-27 |
| JPH08277220A (ja) | 1996-10-22 |
| EP0733365A2 (en) | 1996-09-25 |
| CZ82596A3 (en) | 1996-10-16 |
| IL117537A (en) | 2001-01-11 |
| CA2172211A1 (en) | 1996-09-22 |
| HU9600702D0 (en) | 1996-05-28 |
| IL117537A0 (en) | 1996-07-23 |
| TW450809B (en) | 2001-08-21 |
| ZA962141B (en) | 1997-09-15 |
| AU4816896A (en) | 1996-10-03 |
| EP0733365A3 (en) | 1997-03-05 |
| SG47093A1 (en) | 1998-03-20 |
| CZ287977B6 (cs) | 2001-03-14 |
| YU16196A (sh) | 1998-11-05 |
| NO961113L (no) | 1996-09-23 |
| KR960034202A (ko) | 1996-10-22 |
| HUP9600702A3 (en) | 1997-04-28 |
| HUP9600702A2 (en) | 1996-12-30 |
| MX9601031A (es) | 1997-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0831904A4 (en) | TREATMENT AND DIAGNOSIS OF PROSTATE CANCER | |
| NO971015D0 (no) | Forbindelser og metoder for behandling av cancer | |
| HK1010081A1 (en) | Methods of preventing or treating allergies | |
| FI964874A (fi) | Vihannesten käsittely | |
| NO20002784D0 (no) | Forhindring og behandling av amyloidogen sykdom | |
| NO991700D0 (no) | Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer | |
| IL189132A0 (en) | Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer | |
| HU9602965D0 (en) | Cancer treatment and metastasis prevention | |
| NO955356D0 (no) | Behandling av hypotalamisk amenorre | |
| NO965563D0 (no) | Behandling og profylakse av osteoporese | |
| NO20002189D0 (no) | Anvendelse av makrolider for behandling av cancer og mukuladegenerasjon | |
| DE69836209D1 (de) | Vorbeugung und behandlunhg des hepatozellulären krebses | |
| NO20054619D0 (no) | Sammensetninger og fremgangsmater for behandling av underjordiske formasjoner | |
| NO983512D0 (no) | Midler for behandling og forhindring av AIDS | |
| GB9811598D0 (en) | Diagnosis and treatment of cancer | |
| NO994631D0 (no) | Fremgangsmaater og sammensetninger for behandling av eggstokkreft | |
| NO961226D0 (no) | Blandinger for forebyggelse og behandling av viralinduserte tumorer | |
| NO961113D0 (no) | Behandling og forebyggelse av prostatakreft | |
| NO981662D0 (no) | Diagnosering av disponerhet for kreft og behandling av dette | |
| NO981822L (no) | Anvendelse av proteinet GAX for behandling av cancer | |
| EP0833641A4 (en) | TREATMENT AND PREVENTION OF PROSTATE DISEASES | |
| AU4417996A (en) | Treatment of prostate cancer | |
| GB9516572D0 (en) | Prevention and/or treatment of disease | |
| AU2003204325A1 (en) | Detection and treatment of cancer | |
| KR940002718U (ko) | 치질예방 및 치료기 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |